AbCellera Biologics Inc. (NASDAQ:ABCL) is advancing with Phase 1 studies for two AI-designed antibodies targeting atopic dermatitis and menopausal hot flashes. Dr. Sarah Noonberg appointed as Chief Medical Officer to support expansion into immunological diseases. The company now has 16 molecules in clinical development and 97 partner programs. Plans include launching more clinical trials, expanding manufacturing, and scaling its AI platform. While ABCL shows potential, other AI stocks may offer greater upside. For more insights, check out the best short-term AI stock. No promotional or marketing content is included in the news article.

Read more at Yahoo Finance: New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)’s Push Into Immunology and Beyond